A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice
暂无分享,去创建一个
Jim E Riviere | Zhoumeng Lin | Nancy A Monteiro-Riviere | N. Monteiro-Riviere | J. Riviere | Zhoumeng Lin
[1] Jinatta Jittiwat,et al. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. , 2010, Biomaterials.
[2] S. Gordon,et al. Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.
[3] Lev Dykman,et al. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. , 2011, Chemical Society reviews.
[4] Filip Braet,et al. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review , 2002, Comparative hepatology.
[5] K. Avgoustakis,et al. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content , 2012, International journal of nanomedicine.
[6] Jin Hong,et al. Size-dependent tissue kinetics of PEG-coated gold nanoparticles. , 2010, Toxicology and applied pharmacology.
[7] Jim E Riviere,et al. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. , 2009, Nano letters.
[8] Shraddha S. Nigavekar,et al. Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition , 2012, Pharmaceutical Research.
[9] M. Sheffer,et al. CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT , 2011 .
[10] Rachel A. Kudgus,et al. Intrinsic Therapeutic Applications of Noble Metal Nanoparticles: Past, Present and Future , 2012 .
[11] R. Upton. Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. , 2008, Journal of pharmacological and toxicological methods.
[12] Dhiraj Kumar,et al. Polyethylene glycol functionalized gold nanoparticles: the influence of capping density on stability in various media , 2011 .
[13] Nancy A Monteiro-Riviere,et al. Mechanisms of quantum dot nanoparticle cellular uptake. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[14] Mona Treguer-Delapierre,et al. Impact of dietary gold nanoparticles in zebrafish at very low contamination pressure: The role of size, concentration and exposure time , 2012, Nanotoxicology.
[15] H J Clewell,et al. Derivation of a human equivalent concentration for n-butanol using a physiologically based pharmacokinetic model for n-butyl acetate and metabolites n-butanol and n-butyric acid. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[16] J. Ji,et al. The effect of ligand composition on the in vivo fate of multidentate poly(ethylene glycol) modified gold nanoparticles. , 2013, Biomaterials.
[17] Konrad Hungerbühler,et al. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles , 2013, International journal of nanomedicine.
[18] J. Riviere,et al. Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in edible tissues. , 2005, American journal of veterinary research.
[19] J. Riviere,et al. Estimating meat withdrawal times in pigs exposed to melamine contaminated feed using a physiologically based pharmacokinetic model. , 2008, Regulatory toxicology and pharmacology : RTP.
[20] R. Müller,et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.
[21] Kostas Kostarelos,et al. Physiologically based pharmacokinetic modeling of nanoparticles. , 2010, ACS nano.
[22] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[23] J. Fisher,et al. Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling. , 2013, Toxicology and applied pharmacology.
[24] J. Riviere,et al. Development of a physiologically based pharmacokinetic model for flunixin in cattle (Bos taurus) , 2014, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.
[25] W. D. de Jong,et al. The kinetics of the tissue distribution of silver nanoparticles of different sizes. , 2010, Biomaterials.
[26] Warren C W Chan,et al. Fluorescence‐Tagged Gold Nanoparticles for Rapidly Characterizing the Size‐Dependent Biodistribution in Tumor Models , 2012, Advanced healthcare materials.
[27] J. Fisher,et al. A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. , 2011, Toxicology and applied pharmacology.
[28] Nancy A. Monteiro-Riviere,et al. Cellular uptake mechanisms and toxicity of quantum dots in dendritic cells. , 2011, Nanomedicine.
[29] Olivier Jolliet,et al. Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats , 2014, Nanotoxicology.
[30] Abderrahim Nemmar,et al. Development of a physiologically based kinetic model for 99m-Technetium-labelled carbon nanoparticles inhaled by humans , 2009, Inhalation toxicology.
[31] C. Scoglio,et al. Predicting the impact of biocorona formation kinetics on interspecies extrapolations of nanoparticle biodistribution modeling. , 2015, Nanomedicine.
[32] M. Cesta. Normal Structure, Function, and Histology of the Spleen , 2006, Toxicologic pathology.
[33] R. van Furth,et al. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. , 1972, Bulletin of the World Health Organization.
[34] Nikolai G Khlebtsov,et al. Uptake of engineered gold nanoparticles into mammalian cells. , 2014, Chemical reviews.
[35] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[36] K. Hungerbuhler,et al. Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles , 2015, Nanotoxicology.
[37] R. Gehring,et al. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. , 2015, Journal of pharmaceutical sciences.
[38] Jim E Riviere,et al. Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[39] Robert Landsiedel,et al. Toxico-/biokinetics of nanomaterials , 2012, Archives of Toxicology.
[40] Manuela Semmler-Behnke,et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[41] Bong Hyun Chung,et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. , 2009, Toxicology and applied pharmacology.
[42] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[43] Dong Liang,et al. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. , 2009, Biomaterials.
[44] Jeffrey W Fisher,et al. Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. , 2011, Toxicology and applied pharmacology.
[45] Nathalie Tufenkji,et al. The road to nowhere: equilibrium partition coefficients for nanoparticles , 2014 .
[46] J. Riviere. Of mice, men and nanoparticle biocoronas: are in vitro to in vivo correlations and interspecies extrapolations realistic? , 2013, Nanomedicine.
[47] G. Battaglia,et al. Endocytosis at the nanoscale. , 2012, Chemical Society reviews.
[48] Ming-Hsien Tsai,et al. Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. , 2008, Environmental science & technology.
[49] Patrick Poulin,et al. Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches , 2012, The AAPS Journal.
[50] Jim E Riviere,et al. Pharmacokinetics of metallic nanoparticles. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[51] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[52] Beom Seok Han,et al. Comparison of gene expression profiles in mice liver following intravenous injection of 4 and 100 nm-sized PEG-coated gold nanoparticles. , 2009, Toxicology letters.
[53] D. Bazile,et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.